AIM:To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period.METHOD:Thirty-eight patients with wet type age related macular degeneration(W-AMD)w...AIM:To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period.METHOD:Thirty-eight patients with wet type age related macular degeneration(W-AMD)were involved in this study.Eighteen patients with suboptimal response were shifted to 3 doses monthly intravitreal aflibercept therapy(IVA)and left 20 patients with suboptimal response went on 3 more monthly intravitreal ranibizumab(IVR).All changes were evaluated with fluorescein anigography(FA)and optical coherence tomography(OCT).RESULTS:Preoperative mean visual acuity(VA)and central macular thickness(CMT)of patients were 0.84±0.47 logMAR and 360±84μm,respectively.One month after last IVR and IVA treatments,VA of patients were 1.1±0.34(P=0.11)logMAR and 0.48±0.37(P=0.019)logMAR and CMTs were 300±79μm(P=0.002)and 271±51μm(P=0.002),respectively.CONCLUSION:To eliminate repeated therapy for patients with suboptimal response to ranibizumab therapy,aflibercept might be a good alternative for early visual rehabilitation.展开更多
文摘AIM:To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period.METHOD:Thirty-eight patients with wet type age related macular degeneration(W-AMD)were involved in this study.Eighteen patients with suboptimal response were shifted to 3 doses monthly intravitreal aflibercept therapy(IVA)and left 20 patients with suboptimal response went on 3 more monthly intravitreal ranibizumab(IVR).All changes were evaluated with fluorescein anigography(FA)and optical coherence tomography(OCT).RESULTS:Preoperative mean visual acuity(VA)and central macular thickness(CMT)of patients were 0.84±0.47 logMAR and 360±84μm,respectively.One month after last IVR and IVA treatments,VA of patients were 1.1±0.34(P=0.11)logMAR and 0.48±0.37(P=0.019)logMAR and CMTs were 300±79μm(P=0.002)and 271±51μm(P=0.002),respectively.CONCLUSION:To eliminate repeated therapy for patients with suboptimal response to ranibizumab therapy,aflibercept might be a good alternative for early visual rehabilitation.
